Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081757 · ClinicalTrials.gov registry record · Phase 1
An Open Protocol for the Compassionate Use of Thalidomide
A Phase 1 study of Multiple Myeloma, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00081757: Completed Phase 1 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00081757 is a Phase 1 study of Multiple Myeloma that has completed, run by University of Arkansas. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081757, a Phase 1 study of Multiple Myeloma, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the use of thalidomide for the treatment of cancer. Patients with many types of cancers will be enrolled because the researchers will also study how the different cancers respond and what kind of side effects patients will experience.
Conditions Studied
Interventions
- DRUG Thalidomide
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/MIRT - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 1998-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
What the finished NCT00081757 record still lists
NCT00081757 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.
NCT00081757 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00081757 about?
NCT00081757 is a clinical study titled "An Open Protocol for the Compassionate Use of Thalidomide". The purpose of this study is to evaluate the use of thalidomide for the treatment of cancer. Patients with many types of cancers will be enrolled because the researchers will also study how the different cancers respond and what kind of side effects patients will experience.
What is the current status of trial NCT00081757?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 1998-09. Estimated completion is 2005-05.
What conditions does trial NCT00081757 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00081757?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00081757?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00081757 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00081757's enrollment target sits among peer trials
250 88th of 438 higher than 347 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia